ReproCyc ParvoFLEX Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

reprocyc parvoflex

boehringer ingelheim vetmedica gmbh - parvo svinja, soj 27a, virusni protein 2 - imunološke za suidae - svinje - za aktivne imunizacije popravak svinje i krmače u dobi od 5 mjeseci do zaštitu potomstva od infekcije трансплацентарный uzrokovana parvo svinja.

Enhertu Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

enhertu

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojki - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Enteroporc Coli Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

enteroporc coli

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - imunološke za suidae - svinje - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.

Enteroporc Coli AC Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

enteroporc coli ac

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - svinje - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Focetria Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

focetria

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - cjepiva protiv gripe - profilakcija influence uzrokovana virusom a (h1n1v) 2009. focetria mora se koristiti u skladu sa službenim vodstvom.

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - antigeni virusa influence (hemaglutinin i neuraminidaza) soja a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - cjepiva - aktivna imunizacija protiv h5n1 podtipa virusa gripe a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Prepandrix Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

prepandrix

glaxosmithkline biologicals s.a. - a / indonesia / 05/2005 (h5n1) kao soj koji se koristio (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - cjepiva - aktivna imunizacija protiv h5n1 podtipa virusa gripe a. ovaj prikaz se temelji na imunogenosti podataka od zdravih ispitanika u dobi od 18 i dalje godina nakon uvođenja dvije doze cjepiva, kuhani s podtipa h5n1 sojeva . prepandrix mora se koristiti u skladu sa službenim vodstvom.

Pumarix Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

pumarix

glaxosmithkline biologicals s.a.  - cjepivo protiv pandemijskog gripa (h5n1) (split Вирион, инактивированный, адъювантом) - influenza, human; immunization; disease outbreaks - cjepiva - profilakcija gripe u službeno prijavljenoj pandemijskoj situaciji. pandemije gripe cjepivo bi trebao biti korišten u skladu sa službenim vodstvom.

Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)

glaxosmithkline biologicals s.a. - split virusa influence, inaktiviran, koji sadrži antigen: a / vietnam / 1194/2004 (h5n1) kao soj koji se koristio (nibrg-14) - influenza, human; immunization; disease outbreaks - cjepiva - profilakcija gripe u službeno prijavljenoj pandemijskoj situaciji. cjepivo protiv influence pandemije treba koristiti u skladu s službenim smjernicama.

Boostrix, suspenzija za injekciju u napunjenoj štrcaljki, cjepivo protiv difterije, tetanusa i pertusisa (nestanično, komponentno), adsorbirano, smanjenog(ih) sadržaja antigena Խորվաթիա - խորվաթերեն - HALMED (Agencija za lijekove i medicinske proizvode)

boostrix, suspenzija za injekciju u napunjenoj štrcaljki, cjepivo protiv difterije, tetanusa i pertusisa (nestanično, komponentno), adsorbirano, smanjenog(ih) sadržaja antigena

glaxosmithkline biologicals s.a., rue de l'institut 89, rixensart, belgija - toksoid difterije toksoid tetanusa toksoid hripavca filamentozni hemaglutinin hripavca pertaktin hripavca - suspenzija za injekciju u napunjenoj štrcaljki - 1 doza = 0,5 ml - urbroj: jedna doza (0,5 ml) sadrži: toksoid difterije ne manje od 2 iu (2,5 lf), toksoid tetanusa ne manje od 20 iu (5lf), toksoid hripavca 8 mikrograma, filamentozni hemaglutinin 8 mikrograma, pertaktin 2,5 mikrograma, adsorbirani na aluminijev hidroksid, hidratizirani al (oh)3 0,3 miligrama al 3+ i aluminijev fosfat (alpo4) 0,2 miligrama al 3+